Barrington Research Maintains Outperform on Haemonetics, Raises Price Target to $94

Haemonetics Corporation -0.68% Pre

Haemonetics Corporation

HAE

64.23

64.23

-0.68%

0.00% Pre
Barrington Research analyst Michael Petusky maintains Haemonetics (NYSE: HAE) with a Outperform and raises the price target from $93 to $94.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via